Novo upgrades annual financial forecast following strong demand for the Wegovy pill
Novo reported better-than-expected quarterly financial results on Wednesday morning, driven by exceptionally high sales of its Wegovy pill. The impressive performance prompted the company to elevate its financial outlook for the entire fiscal year. Investors welcomed the robust growth in this key pharmaceutical product.
Open for the full story →